ReviewWorld journal of gastroenterology2013
Clinical application of microRNA in gastric cancer in Eastern Asian area.
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Suppressing SMURF1 to preserve GSTM2: An approach to reducing gastric cancer aggressivenessHistology and histopathology · 2026Article
- Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer.Scientific reports · 2025Article
- Comprehensive analysis of disulfidptosis related genes and prognosis of gastric cancer.World journal of clinical oncology · 2023Article
- MiR-873-5p targets THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance.Journal of gastrointestinal oncology · 2021Article
- [miR-449a/b negatively regulates E2F1 to suppress proliferation of gastric cancer cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Overexpression of miRNA-145 induces apoptosis and prevents proliferation and migration of MKN-45 gastric cancer cells.EXCLI journal · 2020Article
- MiR-1236-3p serves as a new diagnostic and prognostic biomarker for gastric cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- miR-639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma.Oncology letters · 2018Article
- Evaluation of altered expression ofJournal of gastrointestinal oncology · 2018Article
- Role of microRNA-7 in digestive system malignancy.World journal of gastrointestinal oncology · 2016Review
- May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers?Journal of Cancer · 2015Review
- The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review).International journal of oncology · 2015Review
- MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research has shown that microRNA (miRNA), which is involved in almost every step of gastric carcinogenesis, has broad prospective application in diagnosis and therapy of gastric carcinoma. Eastern Asia (South Korea, Japan and China) has the highest incidence of gastric cancer in the world. There were 988,000 new cases of gastric cancer worldwide and 736,000 deaths in 2008. Approximately 60% of the cases of gastric cancer are found in East Asia (mainly China). We herein provide a brief review of the clinical applications of miRNA, which include the following aspects: (1) miRNA may serve as a potential new generation of tumor markers; (2) a complete miRNA expression profile is highly specific, can reflect the evolutionary lineage and differentiation of tumors, and be used to carry out diversity analysis; (3) detecting specific miRNA expression in peripheral blood will become a new method for diagnosis of gastric cancer; (4) miRNA can predict prognosis of gastric cancer; (5) miRNA has predictive value in determining chemotherapy and radiotherapy resistance; and (6) miRNA could be a type of innovative drug. Finally, we focus on assessing the value of miRNA from laboratory to clinical application and the challenges it faces in East Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.